SeraCare Life Sciences Purchases Antibody and Reagent Firm
Established in Maryland in 1979, KPL has developed more than 700 kits and reagents for cell biology, immunology, protein chemistry and molecular biology. End-markets of particular focus for the company include food testing, and diagnostics for diseases such as AIDS, cancer and tropical diseases. Mr. Mamrak told the Boston Business Journal that the acquisition is the first of several planned throughout the next few years. SeraCare operations will move to KPL’s headquarters. In January, SeraCare announced it had restructured its offerings into three business units: IVD Research, IVD Processing and Clinical Laboratory. A SeraCare spokesperson told IBO that the KPL acquisition will be part of the IVD Research business unit. KPL has about 40 employees.
Milford, MA 8/19/13—SeraCare Life Sciences has purchased Kirkegaard & Perry Laboratories (KPL) for an undisclosed amount. KPL develops antibodies and related reagents for life science research and diagnostics. The acquisition will expand SeraCare’s offerings for developing IVD assays. “SeraCare strives to facilitate its customers’ product development efforts, allowing researchers to focus on the science, specifically the design and launch of cutting-edge new assays,” said SeraCare CEO Charles Mamrak. “The addition of KPL will enable SeraCare to more fully meet the needs of these diagnostic researchers, fueling their innovation by providing reliable and qualified materials for use in these assays.” KPL’s immunochemical products include primary and secondary antibodies, and kits and reagents for ELISA, Western blotting, immunohistochemistry, recombinant protein detection and analysis, sample preparation and protein purification, and protein and nucleic acid labeling and detection. The company’s products will help SeraCare broaden its offerings to encompass oncology, autoimmune, allergy and companion diagnostics.
